US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

CLSD Clearside Biomedical Inc

0.9799

-0.0149 (-1.50%)

31 Dic 2024 - Cerrado

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

01/19/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Charles Deignan

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025

Haga Click aquí para más Gráficas Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025

Haga Click aquí para más Gráficas Clearside Biomedical.

Noticias sobre Clearside Biomedical Inc CLSD

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
Jueves 19 de Diciembre 2024 (2 semanas hace) • GlobeNewswire Inc.

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
Lunes 25 de Noviembre 2024 (1 mes hace) • GlobeNewswire Inc.

Form 8-K - Current report
Martes 12 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Martes 12 de Noviembre 2024 (2 meses hace) • GlobeNewswire Inc.

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
Jueves 7 de Noviembre 2024 (2 meses hace) • GlobeNewswire Inc.

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
Miércoles 6 de Noviembre 2024 (2 meses hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 4 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
Lunes 4 de Noviembre 2024 (2 meses hace) • GlobeNewswire Inc.

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
Jueves 31 de Octubre 2024 (2 meses hace) • GlobeNewswire Inc.

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
Martes 22 de Octubre 2024 (2 meses hace) • GlobeNewswire Inc.

Form 8-K - Current report
Miércoles 9 de Octubre 2024 (3 meses hace) • Edgar (US Regulatory)

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
Miércoles 9 de Octubre 2024 (3 meses hace) • GlobeNewswire Inc.

Más de Clearside Biomedical Inc Artículos de Noticias

AEX Total Return Leverage

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones